More extensive research is imperative, focusing on exactly which tumor-infiltrating immune populations express and utilize CD38, what occurs downstream of CD38 upregulation in these immune cells as well as in the tumor cells, and how best to target this complicated molecule in terms of class of inhibitor and potential combinations to improve efficacy. The gene discussed is CD38; the disease is neoplasm.